Molecular stratification and clinical management of adult high-grade glioma
Session type: Parallel sessions
The complex molecular genetic heterogeneity of adult high-grade glioma has precluded prognostic and predictive risk stratification until relatively recently. Emerging biomarkers are presenting new challenges in terms of their functional utility in the context of a limited therapeutic armamentarium: Why do tests if a patient will get the drug anyway?
This session will illustrate the challenges and opportunities of molecular genetic stratification using anaplastic astrocytoma and glioblastoma in the elderly as model systems. The session will conclude with a review of the importance of accurate sampling to interrogate tumour evolution and response to treatment.
This session is aimed at oncologists, surgeons, specialist nurses and scientists interested in improving our understanding and management of patients with high-grade brain cancer.